Copley Scientific has launched the BACTM 2100, an advanced Breath Actuation Controller to help automate flow control when testing metered- dose inhalers (MDIs) for delivered dose uniformity and aerodynamic particle size distribution. 

The new BACTM 2100, which replaces its predecessor, the BACTM 2000, provides flow control for a range of MDI applications, including a time delay feature for the actuation of MDIs when used with spacers and valved holding chambers. It can also be used for flow volume control when testing regular MDIs and for the automatic actuation of breath-actuated MDIs. 

Advanced features include a fully automated in situ cascade impactor leak testing function and extensive data reporting capabilities, with the choice of outputting data to a printer or computer. Test duration is calculated automatically from the required flow volume based on the measured flow rate, derived from a connected flow meter. 

Anna Sipitanou, business development manager at Copley Scientific, said, “After the successful launch of our new TPKTM 2100 we identified the value of transferring much of the technology across to MDIs, where recent additions to the USP chapters relating to MDIs call for a range of parameters to be controlled and monitored, like for DPIs. This need led us to the creation of BACTM 2100 which has been designed specifically for assisting analysts to perform MDI testing in a consistent and reproducible manner, but also eases the process of moving a drug 

application forward by satisfying regulators with robust data reporting functions.” 

In addition to the launch of the new BACTM 2100, a new BACTM 2100-R is also being released. This is a modified version where the flow inlet and outlets are reversed to allow for different arrangements of the test equipment to be located on the laboratory bench.